PDCD1 and neoplasm: Interestingly, the numerous studies exploring the clinical significance of ExoPD-L1 highlighted that, in addition to be correlated with tumor growth and progression, ExoPD-L1 is responsible for mediating resistance to immunotherapy and it should be considered as a potential biomarker in predicting the outcome of anti-PD-1/PD-L1 blockade therapy.